Is there a role for hyperthermic intraperitoneal chemotherapy in ovarian cancer?
Journal
Current opinion in obstetrics & gynecology
ISSN: 1473-656X
Titre abrégé: Curr Opin Obstet Gynecol
Pays: England
ID NLM: 9007264
Informations de publication
Date de publication:
01 02 2023
01 02 2023
Historique:
pmc-release:
01
02
2024
entrez:
3
1
2023
pubmed:
4
1
2023
medline:
6
1
2023
Statut:
ppublish
Résumé
Our objective is to provide a history, rationale, and review of the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of ovarian cancer. In the last decade, there has been an increase in the literature regarding HIPEC in the treatment of ovarian cancer. The rationale for HIPEC extends from earlier trials demonstrating improved survival using intraperitoneal chemotherapy. HIPEC provides a one-time opportunity for intraperitoneal chemotherapy at the time of cytoreduction and with the addition of hyperthermia. Cisplatin HIPEC has been demonstrated to have a survival benefit when used in the interval cytoreductive setting. In terms of safety, nephroprotection remains a key concern when administering HIPEC. Sodium thiosulfate provides nephroprotection and should be considered when performing HIPEC. Various institutions have created multidisciplinary protocols for administering HIPEC, which include operating room staff, nursing, anesthesia, pharmacy, and surgical teams. HIPEC has a role in the treatment paradigm of ovarian cancer. Currently, HIPEC is approved in the interval cytoreductive surgery setting. Further trials are needed to understand the appropriate timing, chemotherapeutic agents, and protocolization of HIPEC.
Identifiants
pubmed: 36595646
doi: 10.1097/GCO.0000000000000837
pii: 00001703-202302000-00005
pmc: PMC10091236
mid: NIHMS1846657
doi:
Types de publication
Review
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
21-26Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Surveillance, Epidemiology, and End Results Program (SEER). Cancer stat facts: ovarian cancer: National Cancer Institute: surveillance, epidemiology, and end results program; 2022. [Available at: https://seer.cancer.gov/statfacts/html/ovary.html ]. [Accessed 1 August 2022]
Cowan RA, O’Cearbhaill RE, Zivanovic O, Chi DS. Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer. Int J Hyperthermia 2017; 33:548–553.
Wright AA, Cronin A, Milne DE, et al. Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancer. J Clin Oncol 2015; 33:2841–2847.
Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354:34–43.
Walker JL, Brady MF, Wenzel L, et al. Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG oncology/gynecologic oncology group study. J Clin Oncol 2019; 37:1380–1390.
Boerner T, Zivanovic O, Chi DS. Narrative review of cytoreductive surgery and intraperitoneal chemotherapy for peritoneal metastases in ovarian cancer. J Gastrointest Oncol 2021; 12: (Suppl 1): S137–S143.
van Stein RM, Aalbers AGJ, Sonke GS, van Driel WJ. Hyperthermic intraperitoneal chemotherapy for ovarian and colorectal cancer: a review. JAMA Oncol 2021; 7:1231–1238.
Zivanovic O, Chi DS, Filippova O, et al. It's time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer. Gynecol Oncol 2018; 151:555–561.
Sugarbaker PH, Van der Speeten K. Ovarian cancer with peritoneal metastases has many treatment options and HIPEC is here to stay. J Gastrointest Oncol 2021; 12: (Suppl 1): S189–S190.
Koole SN, van Driel WJ, Sonke GS. Hyperthermic intraperitoneal chemotherapy for ovarian cancer: the heat is on. Cancer 2019; 125: (Suppl 24): 4587–4593.
Kim SI, Kim JW. Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer. ESMO Open 2021; 6:100149.
Wethington SL, Armstrong DK, Johnston FM. Hyperthermic intraperitoneal chemotherapy for the treatment of epithelial ovarian cancer. JAMA Surg 2022; 157:383.
Kuijpers AM, Mehta AM, Aalbers AG, et al. Treatment of ovarian metastases of colorectal and appendiceal carcinoma in the era of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 2014; 40:937–942.
de Bree E, Michelakis D. An overview and update of hyperthermic intraperitoneal chemotherapy in ovarian cancer. Expert Opin Pharmacother 2020; 21:1479–1492.
Suidan RS, St Clair CM, Lee SJ, et al. A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer. Gynecol Oncol 2014; 134:468–472.
Oseledchyk A, Zivanovic O. Intraoperative hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer. Oncology 2015; 29:695–701.
Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21:3737–3743.
Ni LP, Sun HT, Wang P, et al. Hyperthermia enhances the efficacy of chemotherapeutic drugs in heat-sensitive cells through interfering with DNA damage repair. Ann Transl Med 2022; 10:463.
Moukarzel LA, Ferrando L, Dopeso H, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues. Gynecol Oncol 2022; 165:239–247.
Zivanovic O, Chi DS, Zhou Q, et al. Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: an MSK team ovary phase II study. J Clin Oncol 2021; 39:2594–2604.
Vos LMC, Aronson SL, van Driel WJ, et al. Translational and pharmacological principles of hyperthermic intraperitoneal chemotherapy for ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2022; 78:86–102.
Dellinger TH, Han ES, Raoof M, et al. Hyperthermic intraperitoneal chemotherapy-induced molecular changes in humans validate preclinical data in ovarian cancer. JCO Precis Oncol 2022; 6:e2100239.
van Driel WJ, Koole SN, Sonke GS. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 2018; 378:1363–1364.
Koole S, van Stein R, Sikorska K, et al. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial. Int J Gynecol Cancer 2020; 30:888–892.
Lim MC, Chang SJ, Park B, et al. Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial. JAMA Surg 2022; 157:374–383.
Batista TP, Carneiro VCG, Tancredi R, et al. A phase 2 trial of short-course hyperthermic intraperitoneal chemotherapy (HIPEC) at interval cytoreductive surgery (iCRS) for advanced ovarian cancer. Rev Col Bras Cir 2022; 49:e20223135.
Antonio CCP, Alida GG, Elena GG, et al. Cytoreductive surgery with or without HIPEC after neoadjuvant chemotherapy in ovarian cancer: a phase 3 clinical trial. Ann Surg Oncol 2022; 29:2617–2625.
Lei Z, Wang Y, Wang J, et al. Evaluation of cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for stage III epithelial ovarian cancer. JAMA Netw Open 2020; 3:e2013940.
Ghirardi V, De Felice F, D’Indinosante M, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) after primary debulking surgery in advanced epithelial ovarian cancer: is BRCA mutational status making the difference? Cancer Treat Res Commun 2022; 31:100518.
Koole SN, Schouten PC, Hauke J, et al. Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial. Int J Cancer 2022; 151:1394–1404.
Spiliotis J, Halkia E, Lianos E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 2015; 22:1570–1575.
Strong VE, Selby LV, Sovel M, et al. Development and assessment of Memorial Sloan Kettering Cancer Center's Surgical Secondary Events grading system. Ann Surg Oncol 2015; 22:1061–1067.
Chambers LM, Costales AB, Crean-Tate K, et al. A guide to establishing a hyperthermic intraperitoneal chemotherapy program in gynecologic oncology. Gynecol Oncol 2020; 158:794–802.
Abramian A, Zivanovic O, Kuhn W, et al. Introducing hyperthermic intraperitoneal chemotherapy into gynecological oncology practice – feasibility and safety considerations: single-center experience. Oncol Res Treat 2016; 39:178–184.
Saikia J, Deo S, Ray M, et al. Learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy – an analysis of critical perioperative and surgical outcomes among 155 peritoneal surface malignancy patients treated at a tertiary care cancer centre. Clin Oncol (R Coll Radiol) 2022; 34:e305–e311.
van Stein RM, Lok CAR, Aalbers AGJ, et al. Standardizing HIPEC and perioperative care for patients with ovarian cancer in the Netherlands using a Delphi-based consensus. Gynecol Oncol Rep 2022; 39:100945.
Souadka A, Essangri H, Majbar MA, et al. Hyperthermic intraperitoneal chemotherapy and cytoreductive surgery in ovarian cancer: an umbrella review of meta-analyses. Front Oncol 2022; 12:809773.
Chambers LM, Yao M, Morton M, et al. Perioperative outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in elderly women with epithelial ovarian cancer: analysis of a prospective registry. Int J Gynecol Cancer 2021; 31:1021–1030.
Gruner M, Chambers LM, Yao M, et al. Anastomotic leak following interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian Cancer. Gynecol Oncol 2021; 162:645–651.
Cascales Campos PA, Gonzalez Gil A, Gomez Ruiz AJ, et al. Interval cytoredutive surgery and HIPEC in advanced ovarian cancer with small-bowel disease: results and reflections. Clin Transl Oncol 2022; 24:1542–1548.
Ferron G, Simon L, Guyon F, et al. Professional risks when carrying out cytoreductive surgery for peritoneal malignancy with hyperthermic intraperitoneal chemotherapy (HIPEC): a French multicentric survey. Eur J Surg Oncol 2015; 41:1361–1367.
van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 2018; 378:230–240.
Glennon K, Mulligan K, Carpenter K, et al. The addition of sodium thiosulphate to hyperthermic intraperitoneal chemotherapy with cisplatin in ovarian cancer. Gynecol Oncol Rep 2021; 37:100796.
Penn CA, Carballo EV, Walsh CS, et al. Cost-effectiveness of hyperthermic intraperitoneal chemotherapy at primary cytoreduction of epithelial ovarian cancer based on residual disease status. Gynecol Oncol Rep 2022; 41:101009.